**Lineage Cell Therapeutics Reports Financial Results and Operational Progress in 10-K Filing**
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company focused on cell replacement therapies, released its 10-K filing, detailing its financial performance and operational achievements. The company reported total revenues of $14.6 million for the year ended December 31, 2025, a 53% increase compared to $9.5 million in 2024. This growth was primarily driven by a $5.5 million increase in collaboration revenues, stemming from a milestone payment under the Roche agreement for OpRegen and revenue from a new collaboration with William Demant Invest (WDI) for ReSonance. Royalties, license, and other revenues decreased by $0.4 million to $0.9 million. The company's operating losses totaled $36.6 million in 2025, compared to $21.5 million in the previous year.
The company's research and development expenses increased by 42% to $17.7 million in 2025, reflecting ongoing investments in its pipeline programs, including OpRegen, OPC1, and ReSonance. General and administrative expenses saw a slight increase of 2% to $18.5 million. A significant factor impacting the company's financial results was a $14.8 million loss on impairment of an intangible asset related to the VAC platform, which was abandoned during the year. Net loss attributable to Lineage was $63.5 million, or $0.28 per share, compared to a net loss of $18.6 million, or $0.09 per share, in 2024.
Operationally, Lineage highlighted several key achievements, including the successful execution of its contributions to the Roche collaboration for OpRegen, achieving the first milestone under the Roche agreement, and reporting durable improvement in visual acuity in dry AMD patients treated with OpRegen. The company also treated the first chronic spinal cord injury patient using a novel delivery device in an OPC1 clinical study and entered into a collaboration with WDI to advance the preclinical development of ReSonance for hearing loss. As of December 31, 2025, Lineage had 77 employees, with 22 at Lineage and 55 at its subsidiary Cell Cure Neurosciences Ltd. (CCN) in Israel.
Looking ahead, Lineage emphasized its strategy to leverage its AlloSCOPE platform to create a pipeline of cell-based assets, with plans to advance some internally and partner others. The company anticipates that its existing cash, cash equivalents, and marketable securities will be sufficient to fund planned operations for at least the next twelve months. However, additional capital will be needed to advance product candidates through regulatory approval and commercialization. The company plans to explore various funding options, including equity offerings, debt financings, strategic alliances, and grants. The company also noted that its manufacturing operations are currently conducted at its facility in Jerusalem, Israel, and that the ongoing Israeli regional conflict may pose risks to its operations and ability to raise additional capital.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics develops off-the-shelf allogeneic cell therapies targeting neurological and ophthalmic conditions. Its programs include retinal cell replacement for age-related macular degeneration and spinal cord injury repair using pluripotent stem cell-derived cells. The company leverages proprietary differentiation, manufacturing, and delivery technologies, collaborating with partners like Roche. Its focus is on regenerative treatments that restore or support damaged tissues, with a pipeline spanning clinical and preclinical stages.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.